Overview
Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Erik Manting, CEO.
Phone: +46(0)8 732 8400
Email: ir@immunicum.com
CEO statement, March 16, 2021
“I am looking forward to leading Immunicum as it embarks on this next phase of its development following the merger with DCprime. Following the merger, Immunicum is a company with a rich, advanced clinical pipeline, in-house research and process development capabilities and leading science in allogeneic dendritic cell biology, putting us in a position of strength to build a global biopharmaceutical company in the field of cancer immunotherapies. The combined company has strong expertise throughout the organization and this new executive management team, resulting from a constructive integration process, allows us to define a long-term strategy that drives the further development of our products in blood-borne and solid tumor indications with multiple clinical milestones expected in the second half of this year.”– Erik Manting, CEO
Investor Downloads
